ARTICLE | Management Tracks
Plus: David Cameron named chair of Oxford-Harrington Rare Disease Centre’s advisory council, and updates from Twist, Boundless, Lucy and more
By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst
October 15, 2024 11:15 PM UTC
Boundless Bio Inc. (NASDAQ:BOLD) announced the departure of CFO Jami Rubin, who is leaving the San Diego-based biotech for personal reasons. Boundless named SVP Finance and Controller David Hinkle principal financial and accounting officer and said the company does not plan to hire a new CFO. Rubin joined Boundless in July 2023 and took the company public this year, shortly before it announced plans to extend its operating runway by scaling back early discovery work.
Three companies hired new CSOs. Paige Mahaney will become CSO of C4 Therapeutics Inc. (NASDAQ:CCCC) on Oct. 28, succeeding Stewart Fisher, who is retiring. Mahaney was SVP and corporate head of drug discovery at Exelixis Inc. (NASDAQ:EXEL)…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653882/rubin-leaving-boundless-as-cfo-new-csos-for-c4-avacta-and-commit